First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results

被引：17
|
作者：
Hamid, Omid
Thompson, John A.
Diab, Adi
Ros, Willeke
Eskens, Ferry
Bermingham, Candy
Konto, Cyril
Long, Hua
Liao, Ken
Ganguly, Bishu J.
Fleener, Catherine
Pleasic-Williams, Susan
Garzone, Pamela D.
Patel, Premal H.
Joh, Tenshang
Nuyten, Dimitry S. A.
El-Khoueiry, Anthony B.
机构：
[1] Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[6] Rinat Pfizer, San Francisco, CA USA
[7] Pfizer, San Francisco, CA USA
[8] Pfizer, San Diego, CA USA
[9] Pfizer, Groton, CT USA
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3079
引用
收藏
页数：2
相关论文
共 16 条
  • [1] A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies
    Diab, A.
    El-Khoueiry, A.
    Eskens, F. A.
    Ros, W.
    Thompson, J. A.
    Konto, C.
    Bermingham, C.
    Joh, T.
    Liao, K.
    Ganguly, B.
    Hamid, O.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)
    Diab, Adi
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Fredericus A. L. M.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Long, Hua
    Joh, Tenshang
    Potluri, Shoba
    Wang, Xiao
    Fleener, Catherine
    Taylor, Carrie Turich
    Ganguli, Bishu J.
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb
    Hamid, O.
    Ros, W.
    Thompson, J. A.
    Hu-Lieskovan, S.
    Eskens, F. A. L. M.
    Diab, A.
    Doi, T.
    Wasser, J.
    Spano, J-P.
    Rizvi, N. A.
    Angevin, E.
    Chiappori, A.
    Ott, P. A.
    Ganguly, B. J.
    Fleener, C.
    Dell, V.
    Liao, K.
    Joh, T.
    Chou, J.
    El-Khoueiry, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of 0X40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).
    El-Khoueiry, Anthony B.
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Ferry
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Chou, Jeffrey
    Liao, Ken
    Ganguly, Bishu J.
    Fleener, Catherine
    Joh, Tenshang
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
    Glisson, B. S.
    Leidner, R.
    Ferris, R. L.
    Powderly, J.
    Rizvi, N.
    Norton, J. D.
    Burton, J.
    Lanasa, M. C.
    Patel, S. P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
    Glisson, Bonnie S.
    Leidner, Rom S.
    Ferris, Robert L.
    Powderly, John
    Rizvi, Naiyer A.
    Keam, Bhumsuk
    Schneider, Reva
    Goel, Sanjay
    Ohr, James P.
    Burton, Jennifer
    Zheng, Yanan
    Eck, Steven
    Gribbin, Matthew
    Streicher, Katie
    Townsley, Danielle M.
    Patel, Sandip Pravin
    CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5358 - 5367
  • [7] Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
    Glisson, B.
    Leidner, R.
    Ferris, R. L.
    Powderly, J.
    Rizvi, N. A.
    Keam, B.
    Schneider, R.
    Goel, S.
    Ohr, J. P.
    Zheng, Y.
    Eck, S.
    Gribbin, M.
    Townsley, D. M.
    Chiou, V.
    Patel, S. P.
    ANNALS OF ONCOLOGY, 2018, 29 : 410 - 410
  • [8] Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
    Jones, S. F.
    Burris, H. A., III
    Dumez, H.
    Infante, J. R.
    Fowst, C.
    Gerletti, P.
    Xu, H.
    Jakubczak, J.
    Mellaerts, N.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors
    El-Khoueiry, Anthony B.
    Garralda, Elena
    Cervantes, Andres
    Haddox, Candace L.
    Babiker, Hani M.
    Borad, Mitesh J.
    Leventakos, Konstantinos
    Mehra, Ranee
    Zugazagoitia, Jon
    Hanna, Diana L.
    Alonso, Guzman
    Liu, Angela
    Shi, Xiaorong
    Pollard, Jack Russella
    Wong, Gabrielle
    Hedrich, William
    Lin, Xi
    Hatzis, Christos
    Pallante, John
    Andtbacka, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] PHARMACODYNAMIC (PD) - PHARMACOKINETIC (PK) STUDY OF FICLATUZUMAB(F), A MONOCLONAL ANTIBODY (MAB) DIRECTED TO THE HEPATOCYTE GROWTH FACTOR (HGF), IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS WHO HAVE LIVER METASTASES (METS)
    Elez, E.
    Tabernero, J.
    Prudkin, L.
    Agarwal, S.
    Han, M.
    Credi, M.
    Yin, W.
    Kuriyama, N.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 154 - 154
12